DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes

Overview

Journal Inflammation

Specialties Allergy & Immunology
Pathology

Date 2019 Feb 2

PMID 30707388

Citations 5

Authors

Mariana Rodrigues Davanso

Carolina Caliari-Oliveira

Carlos Eduardo Barra Couri

Dimas Tadeu Covas

Angela Merice de Oliveira Leal

Julio Cesar Voltarelli

Kelen Cristina Ribeiro Malmegrim

Juliana Navarro Ueda Yaochite

Affiliations

Soon will be listed here.

Abstract

Sitagliptin is a dipeptidyl peptidase-4 inhibitor (iDPP-4), which has been used for type 2 diabetes treatment. Recently, iDPP-4 has been described as a promising treatment of type 1 diabetes (T1D) but is still necessary to evaluate immune effects of sitagliptin. C57BL/6 mice were induced by multiple low doses of streptozotocin. Diabetes incidence, insulin, glucagon, glucagon-like peptide-1 (GLP-1) serum levels, and inflammatory cytokine levels were quantified in pancreas homogenate after 30 and 90 days of treatment. In addition, frequencies of inflammatory and regulatory T cell subsets were determined in the spleen and in the pancreatic lymph nodes. iDPP-4 decreased blood glucose level while increased GLP-1 and insulin levels. After long-term treatment, treated diabetic mice presented decreased frequency of CD4CD26 T cells and increased percentage of CD4CD25Foxp3 T cells in the spleen. Besides, pancreatic lymph nodes from diabetic mice treated with iDPP-4 presented lower percentage of CD11b cells and decreased levels of inflammatory cytokines in the pancreas. Treatment of type 1 diabetic mice with iDPP-4 improved metabolic control, decreased inflammatory profile in the pancreatic microenvironment, and increased systemic regulatory T cell frequency. Therefore, we suggest the long-term use of sitagliptin as a feasible and effective therapy for T1D.

Citing Articles

Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors.

Rahim K, Shan M, Ul Haq I, Nawaz M, Maryam S, Alturki M J Inflamm Res. 2024; 17:1897-1917.

PMID: 38544813 PMC: 10968008. DOI: 10.2147/JIR.S442106.

Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.

Huang J, Liu X, Wei Y, Li X, Gao S, Dong L Front Immunol. 2022; 13:830863.

PMID: 35309368 PMC: 8931313. DOI: 10.3389/fimmu.2022.830863.

Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus.

Penaforte-Saboia J, Couri C, Albuquerque N, Lauanna Lima Silva V, da Cunha Olegario N, Fernandes V Diabetes Metab Syndr Obes. 2021; 14:565-573.

PMID: 33603422 PMC: 7882449. DOI: 10.2147/DMSO.S294742.

Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1β and IL-12 in NOD mice.

He X, Li W, Xie Y, Zhao Y Int Immunopharmacol. 2020; 88:106945.

PMID: 33182020 PMC: 7510641. DOI: 10.1016/j.intimp.2020.106945.

Klotho Ameliorates Cellular Inflammation via Suppression of Cytokine Release and Upregulation of miR-29a in the PBMCs of Diagnosed Alzheimer's Disease Patients.

Sedighi M, Baluchnejadmojarad T, Fallah S, Moradi N, Afshin-Majdd S, Roghani M J Mol Neurosci. 2019; 69(1):157-165.

PMID: 31197641 DOI: 10.1007/s12031-019-01345-5.

References

De Meester I, Korom S, Van Damme J, Scharpe S . CD26, let it cut or cut it down. Immunol Today. 1999; 20(8):367-75. DOI: 10.1016/s0167-5699(99)01486-3. View

Tourrel C, Bailbe D, Meile M, Kergoat M, Portha B . Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 2001; 50(7):1562-70. DOI: 10.2337/diabetes.50.7.1562. View

Pospisilik J, Stafford S, Demuth H, Brownsey R, Parkhouse W, Finegood D . Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes. 2002; 51(4):943-50. DOI: 10.2337/diabetes.51.4.943. View

Pospisilik J, Stafford S, Demuth H, McIntosh C, Pederson R . Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes. 2002; 51(9):2677-83. DOI: 10.2337/diabetes.51.9.2677. View

Pospisilik J, Martin J, Doty T, Ehses J, Pamir N, Lynn F . Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003; 52(3):741-50. DOI: 10.2337/diabetes.52.3.741. View

Fan H, Yan S, Stehling S, Marguet D, Schuppaw D, Reutter W . Dipeptidyl peptidase IV/CD26 in T cell activation, cytokine secretion and immunoglobulin production. Adv Exp Med Biol. 2003; 524:165-74. DOI: 10.1007/0-306-47920-6_20. View

Brubaker P, Drucker D . Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004; 145(6):2653-9. DOI: 10.1210/en.2004-0015. View

Baggio L, Drucker D . Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med. 2006; 57:265-81. DOI: 10.1146/annurev.med.57.110104.115624. View

Drucker D . The biology of incretin hormones. Cell Metab. 2006; 3(3):153-65. DOI: 10.1016/j.cmet.2006.01.004. View

10.

Drucker D, Nauck M . The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368(9548):1696-705. DOI: 10.1016/S0140-6736(06)69705-5. View

11.

Drucker D . The role of gut hormones in glucose homeostasis. J Clin Invest. 2007; 117(1):24-32. PMC: 1716213. DOI: 10.1172/JCI30076. View

12.

Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, Takahashi N . Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem. 2007; 282(13):10117-10131. DOI: 10.1074/jbc.M609157200. View

13.

Baggio L, Drucker D . Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132(6):2131-57. DOI: 10.1053/j.gastro.2007.03.054. View

14.

Hadjiyanni I, Baggio L, Poussier P, Drucker D . Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology. 2007; 149(3):1338-49. PMC: 2275367. DOI: 10.1210/en.2007-1137. View

15.

Kim S, Nian C, Doudet D, McIntosh C . Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes. 2008; 57(5):1331-9. DOI: 10.2337/db07-1639. View

16.

Kim S, Nian C, Doudet D, McIntosh C . Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes. 2008; 58(3):641-51. PMC: 2646063. DOI: 10.2337/db08-1101. View

17.

Xue S, Wasserfall C, Parker M, Brusko T, Mcgrail S, McGrail K . Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann N Y Acad Sci. 2009; 1150:152-6. DOI: 10.1196/annals.1447.049. View

18.

Couri C, Oliveira M, Stracieri A, Moraes D, Pieroni F, Barros G . C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009; 301(15):1573-9. DOI: 10.1001/jama.2009.470. View

19.

Josefowicz S, Rudensky A . Control of regulatory T cell lineage commitment and maintenance. Immunity. 2009; 30(5):616-25. PMC: 4410181. DOI: 10.1016/j.immuni.2009.04.009. View

20.

Kim S, Nian C, McIntosh C . Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways. Diabetes. 2010; 59(7):1739-50. PMC: 2889774. DOI: 10.2337/db09-1618. View